Patients with manifestations compatible with multisystem inflammatory syndrome in children (MIS-C) were first identified in April 2020 during the height of the COVID-19 pandemic in the United Kingdom.
1 Patients had hyperinflammatory shock with features similar to Kawasaki disease and toxic shock syndrome. The report alerted clinicians and public health authorities worldwide, and similar patients were subsequently identified in Europe, the United States, and other countries.
2-7 Most patients with MIS-C presented with fever, signs of generalized inflammation, hypotension and shock, and multiple organ dysfunction.
7,8